Case Report
Accepted on 05 Jul 2024
Case report: Durable Response of Ensartinib Targeting EML4-ALK Fusion in Osimertinib-resistant Non-small Cell Lung Cancer
in Pharmacology of Anti-Cancer Drugs
Case Report
Accepted on 05 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Review
Published on 05 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Published on 05 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Review
Published on 04 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Mini Review
Published on 04 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Correction
Accepted on 03 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Brief Research Report
Published on 03 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Review
Published on 03 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 02 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 01 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Published on 01 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Perspective
Published on 01 Jul 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Published on 28 Jun 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Published on 28 Jun 2024
in Pharmacology of Anti-Cancer Drugs
Opinion
Published on 27 Jun 2024
in Pharmacology of Anti-Cancer Drugs
Review
Published on 27 Jun 2024
in Pharmacology of Anti-Cancer Drugs